Genetic Medicine & Rare Mutations: Hopes Ahead
- PHILADELPHIA (AP) — For Emily Kramer-Golinkoff, each breath is a struggle.Advanced cystic fibrosis,a genetic disease,makes everyday activities like walking or showering exhausting.
- This scenario is mirrored across various genetic conditions, where advancements in genetic science have illuminated the causes of these diseases and spurred treatment development.
- "we feel pure joy for our friends who have been rescued," said Kramer-Golinkoff, 40. "But we feel anxious and desperate to join them.
gene Therapy Offers Hope for Cystic Fibrosis Patients with Rare Mutations
Table of Contents
PHILADELPHIA (AP) — For Emily Kramer-Golinkoff, each breath is a struggle.Advanced cystic fibrosis,a genetic disease,makes everyday activities like walking or showering exhausting. Kramer-Golinkoff is among the 40,000 Americans living with cystic fibrosis, but her specific genetic mutation is rare, rendering standard treatments ineffective.
This scenario is mirrored across various genetic conditions, where advancements in genetic science have illuminated the causes of these diseases and spurred treatment development. However, individuals with extremely rare mutations often face limited options, placing their hopes on experimental gene therapies.
“we feel pure joy for our friends who have been rescued,” said Kramer-Golinkoff, 40. “But we feel anxious and desperate to join them. It is indeed really difficult to be in this minority of people who are left behind.”
The challenge extends beyond scientific hurdles; market forces also play a role. Pharmaceutical companies prioritize medications targeting the most common mutations.
“You need a sufficiently large number of patients in an meaningful market for a company to be interested in advancing,” said Dr. Kiran Musunuru, a genetic editing expert at the University of Pennsylvania.He describes this as “mutational discrimination.”
Organizations like Emily’s Entourage, a nonprofit co-founded by Kramer-Golinkoff, are working to overcome this obstacle. Fundraising efforts are supporting gene therapy research that could benefit patients regardless of their specific mutation.
While widespread availability is still years away, Kramer-Golinkoff remains optimistic. “The simple fact of having these therapies in trials provides much hope,” she said.
Current Treatments Fall Short for Many
Kramer-Golinkoff was diagnosed with cystic fibrosis at six weeks old. The disease leads to the accumulation of thick, sticky mucus throughout the body.
Cystic fibrosis occurs when the CFTR protein is either absent or malfunctioning, causing chloride to become trapped in cells. This prevents water from hydrating the cell surface,leading to mucus buildup that can damage the lungs and other organs.
“As I aged… my cystic fibrosis has worsened,despite all my best efforts to delay it,” kramer-Golinkoff said.
before her condition deteriorated significantly, she earned a master’s degree in Bioethics from the University of Pennsylvania, worked, traveled, and spent time with friends. However, she eventually developed cystic fibrosis-related diabetes and other complications. Prone to infections, she has been living in isolation with her parents in the Philadelphia area since the pandemic began.
“Cystic fibrosis is a true disease monster,” she said.
Meanwhile, others with cystic fibrosis have experienced significant health improvements through CFTR modulator therapies, which correct the defective protein in individuals with common mutations. Studies show these therapies drastically improve pulmonary function, respiratory symptoms, and overall quality of life.
Though, these treatments are ineffective for those with rare mutations or whose disease-causing mutations are unknown or poorly understood. Undetected mutations can stem from limited genetic data in developing nations or insufficient research into unusual or difficult-to-detect mutations.
Genetic testing companies are improving the detection rates across diverse populations, but disparities persist. For instance, comprehensive cystic fibrosis data is lacking for African populations, impacting both those living on the continent and those with African ancestry. Research indicates that Black cystic fibrosis patients are more likely than their white counterparts to be among the estimated 10% who do not benefit from modulator therapies.
Mutation-Agnostic Gene Therapy: A Potential Solution?
Researchers suggest that developing mutation-agnostic therapies, which target all patients with a disease regardless of their specific mutation, could overcome market limitations. This approach is being explored not only in cystic fibrosis but also in retinal diseases.
“Ther is a great boost to develop these therapies,” said Dr. Garry Cutting of the Johns Hopkins cystic fibrosis center.
According to the Cystic Fibrosis Foundation, most of the 14 experimental gene therapies currently in development aim to deliver a correct version of the CFTR gene to cells, benefiting patients with any mutation. Functional CFTR genes would enable cells to produce normal proteins, regardless of the underlying mutation.
One such treatment, partially funded by the Cystic Fibrosis Foundation, is sponsored by Spirovant Sciences, a company that received initial capital from Emily’s Entourage. The first patient received the therapy in November as part of a 53-week clinical trial at Columbia University, designed to assess its safety and duration of effect in the lungs.
Despite her worsening condition, Kramer-Golinkoff expresses increased optimism about the future. Currently, she has 30% lung function, suffers from kidney problems, and experiences high blood pressure in her lungs. She relies on insulin for diabetes and takes multiple medications daily.
“You must make really aware decisions… throughout the day on how to use your limited energy. And that is really difficult to do when you have great dreams and critically important work and life to live,” she said.
“We are incredibly excited by the promise of gene therapies. They cannot arrive sufficiently.”
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Okay, here’s a Q&A-style blog post crafted from the provided article content. I’ve focused on providing value, strong E-E-A-T signals, and optimized it for readability and comprehension.
Gene Therapy: Hope for Cystic Fibrosis Patients with Rare Mutations
(Note: This article is for informational purposes only and is not a substitute for professional medical advice. Always consult with your doctor for diagnosis and treatment.)
Q: What is cystic fibrosis (CF), and why is it so challenging to treat?
A: Cystic fibrosis is a genetic disease that primarily affects the lungs, but also impacts other organs like the pancreas, liver, and intestines. It leads to the accumulation of thick,sticky mucus throughout the body.This buildup can cause severe breathing problems, frequent infections, and damage to vital organs.In a nutshell, it’s a tough condition.
The underlying cause of CF is a malfunctioning or absent CFTR protein.this protein plays a crucial role in regulating chloride transport, which in turn affects water balance on cell surfaces.When the CFTR protein doesn’t function correctly, chloride becomes trapped inside cells, preventing water from hydrating the cell surface. This lack of hydration leads to the thick mucus that characterizes CF.
Q: How are current treatments for cystic fibrosis failing some patients?
A: While important advances have been made in treating cystic fibrosis, existing therapies aren’t a “one size fits all” solution. Current treatments like CFTR modulator therapies have dramatically improved the health and quality of life for many individuals. However, these modulators work by correcting the defective CFTR protein only in those with common genetic mutations. They aren’t effective for individuals with rare mutations or those with mutations that are either unknown or poorly understood.This is why many patients with rare mutations “fall through the cracks.”
Q: What are rare mutations, and why are they a problem in CF treatment?
A: rare mutations are specific genetic changes that cause cystic fibrosis but aren’t as common as others. Genetic testing can identify many of the common mutations, allowing for targeted treatments like modulators. However, there are thousands of potential mutations, and many are considered “rare.”
The challenge is that the pharmaceutical companies prioritize the development of medications targeting the most common mutations because the potential market is larger. The focus on the most common mutations leaves patients with rare mutations struggling to find options. As Dr. Kiran Musunuru, a genetic editing expert at the University of Pennsylvania, saeid It is “mutational discrimination”.
Q: How does the “mutational” discrimination influence the market and treatment for individuals with rare mutations?
A: the market forces are driven by potential profits. Pharmaceutical companies invest heavily in developing treatments that have the potential to reach a large number of patients. The financial incentive to create mutation-specific treatments for rare mutations is frequently much smaller. This makes it a challenge for the scientific community and for patients to be able to find a treatment for those with uncommon mutations.
Q: What is mutation-agnostic gene therapy, and how does it offer a ray of hope?
A: Mutation-agnostic gene therapy is a new approach that could be a game-changer, and the promise of this treatment is very compelling. Instead of targeting a specific mutation, this approach aims to address CF at its core: by delivering a correct, functional version of the CFTR gene to the cells.This approach would address the underlying genetic defect irrespective of the particular genetic mutation that is involved. The idea is to restore normal CFTR protein production,allowing cells to function correctly and alleviating the symptoms of CF.
Q: How does gene therapy work?
A: Gene therapy is a cutting-edge approach that involves providing a “correct” version of a gene to replace or supplement a faulty one. In the context of cystic fibrosis, gene therapy aims to deliver a functioning CFTR gene to the cells in the lungs and other affected organs. When the functional CFTR gene is present, the cells can then create the normal CFTR protein, leading to improved chloride transport and reduced mucus buildup.
Q: Are there mutation-agnostic therapies also being explored for other diseases and conditions?
A: Yes.Researchers are not only exploring mutation-agnostic gene therapy for cystic fibrosis but also for other conditions such as retinal (eye) diseases.
Q: What are the benefits of mutation-agnostic gene therapy?
A: Mutation-agnostic therapies could provide a major boost to patients. Those who do not benefit from current therapies, or those with rare mutations, could find relief and health improvements using gene therapy.
Q: what are the current gene therapy trials?
A: Currently, there are approximately 14 experimental gene therapies in development. Many of these treatments are aimed at delivering a correct version of the CFTR gene to cells. One therapy, partially funded by the Cystic Fibrosis Foundation, is sponsored by Spirovant sciences. It is in a 53-week clinical trial at Columbia University.Patients are now beginning to receive treatments.
Q: What are the challenges and obstacles facing gene therapy development?
A: Gene therapy is still in its early stages of development, and it comes with challenges: the main concern is how the treatments will affect the human body. Additionally, the cost and the path to wider application for patients are huge challenges.
Q: What gives Emily Kramer-Golinkoff hope for the future?
A: Despite the challenges, Emily Kramer-Golinkoff, diagnosed with CF at six weeks old, is optimistic. She remains hopeful because there are therapies currently in trials. And there has been a great advancement in finding treatments.
Q: How can organizations and individuals help advance gene therapy research?
A: Organizations like Emily’s Entourage and the Cystic Fibrosis Foundation are playing a vital role. They help overcome hurdles like market limitations. these organizations provide the funding and support that accelerate the research and development of new therapies.
Q: What is the outlook for individuals with cystic fibrosis?
A: The future looks hopeful. The development of gene therapies and the research progress are a great achievement for the Cystic Fibrosis community. It is an exciting time, and Emily Kramer-Golinkoff said It is a promise that cannot arrive fast enough.
(Disclaimer: The information in this article is for informational purposes only and is not a substitute for professional medical advice. Always consult with your doctor for diagnosis and treatment.)